Skip to main content
. 2020 Dec 4;12(12):3648. doi: 10.3390/cancers12123648

Figure 2.

Figure 2

Forest plot of pembrolizumab + chemotherapy vs nivolumab + ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS ≥1%. Note: The results illustrated with the yellow lines refer to the base case analysis. IPD: individual patient data; PD-L1: Programmed cell death ligand 1; TPS: tumor proportion score.